J Tusell

DiarrheagenicEscherichia coli

Tailored prophylaxis in severe hemophilia A: interim results from the first 5 years of the Canadian Hemophilia Primary Prophylaxis Study

Consensus protocol for the use of recombinant activated factor VII [eptacog alfa (activated); NovoSeven^®] in elective orthopaedic surgery in haemophilic patients with inhibitors

The risk associated with indwelling catheters in children with haemophilia

Exercise and sport in the treatment of haemophilic patients: a systematic review

Platelet Count and Prothrombin Time Help Distinguish Thrombotic Thrombocytopenic Purpura–Hemolytic Uremic Syndrome From Disseminated Intravascular Coagulation in Adults

Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence‐based approaches

Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome

Recommendations for assessment, monitoring and follow‐up of patients with haemophilia

Psycho‐social determinants of quality of life in children and adolescents with haemophilia—a cross‐cultural approach

Implantable central venous access device procedures in haemophilia patients without an inhibitor: systematic review of the literature and institutional experience

Health‐related quality of life in a cohort of adult patients with mild hemophilia A

Activation of both coagulation and fibrinolysis in childhood hemolytic uremic syndrome

Immune Thrombocytopenic Purpura

Central venous access devices in haemophilia

Haemophilic arthropathy of the ankle treated by total ankle replacement: a case series

Long‐term major joint outcomes in young adults with haemophilia: interim data from the HGDS

Haemophilias A and B

Blood Products for Hemophilia

Surgery and inhibitor development in hemophilia A: a systematic review

Protein therapeutics: a summary and pharmacological classification

Guidelines on the Use of Therapeutic Apheresis in Clinical Practice – Evidence‐Based Approach from the Writing Committee of the American Society for Apheresis: The Eighth Special Issue

Tumor necrosis factor and interleukin-1 induce expression of the verocytotoxin receptor globotriaosylceramide on human endothelial cells: implications for the pathogenesis of the hemolytic uremic syndrome

The effects of postponing prophylactic treatment on long-term outcome in patients with severe hemophilia

Pregnancy-associated thrombocytopenia: pathogenesis and management

Anticancer potential of curcumin: preclinical and clinical studies.

Verotoxin-1 induces tissue factor expression in human umbilical vein endothelial cells through activation of NF-kappaB/Rel and AP-1.

Human recombinant factor IX: safety and efficacy studies in hemophilia B patients previously treated with plasma-derived factor IX concentrates

A reporter transgene indicates renal-specific induction of tumor necrosis factor (TNF) by shiga-like toxin. Possible involvement of TNF in hemolytic uremic syndrome.

Pathogenesis and Diagnosis of Shiga Toxin-Producing Escherichia coli Infections

Guidelines for the management of hemophilia

The orthopaedic status of severe haemophiliacs in Spain

European Study on Orthopaedic Status of haemophilia patients with inhibitors

Results of an orthopaedic survey in young patients with severe haemophilia in Spain

Seroprevalence of parvovirus B19, cytomegalovirus, hepatitis A virus and hepatitis E virus antibodies in haemophiliacs treated exclusively with clotting‐factor concentrates considered safe against human immunodeficiency and hepatitis C viruses

Treatment of children with haemophilia in Europe: a survey of 20 centres in 16 countries

Pilot testing of the ‘Haemo‐QoL’ quality of life questionnaire for haemophiliac children in six European countries

Thrombin Generation and Fibrinolysis in the Thrombotic Thrombocytopenic Purpura and the Hemolytic-Uremic Syndrome